Douglas Mack, MD, discusses the upcoming phase 2 THRIVE trial assessing the Viaskin Peanut patch in infants aged 6 through 12 months with peanut allergy.
Douglas P. Mack
Advertisement
Douglas P. Mack, a pediatric allergist and assistant clinical professor at McMaster University
Articles by Douglas P. Mack
Research presented at AAAAI 2026 found that 88% of participants preferred intranasal epinephrine over injectables.
A randomized crossover study shows that most patients prefer intranasal epinephrine for anaphylaxis due to its ease of use, portability, and the absence of needles.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
New Topicals in Atopic Dermatitis: Evidence, Barriers, and Real-World Perspectives
2
Atacicept and Upstream Immune Targeting in IgAN With Richard Lafayette, MD
3
Enlicitide’s FDA Approval for LDL-C Reduction and the CORALreef Outcomes Trial
4
Culprits in Perioperative Allergy, With Kimberly Blumenthal, MD
5